In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Delo...(g discovery development andrealization t...)

Date:6/17/2008

g discovery, development and realization to measure the inputs and outputs of innovation during the process of bringing new products to market. The six key innovations were selected based on their impact on patient care and health outcomes: targeted therapies with companion molecular diagnostics, monoclonal antibodies (MAbs), stem cell therapy, RNA interference (RNAi), drug device combinations and radiotherapy.

Additional benchmark findings based on data from the Deloitte report indicate:

-- Targeted therapies with companion molecular diagnostics - Have quickly

progressed from idea to realization as a number of new products entered

the market in the last few years. Discovery innovation remains active

and development continues.

-- Monoclonal antibodies - Have achieved widespread clinical acceptance in

the past three years after more than 20 years of variable progress.

However, the volume of discovery innovations has dropped off as they

move into the next stage, development. New structures and methods have

resulted in a fresh set of innovations, some of which are already in

the clinic.

-- Stem cells - Have achieved a high level of discovery innovation over

the past six years; however realization and development have not yet

occurred.

-- RNAi - As a newer technology in the area of therapeutic treatment, RNAi

experienced discovery innovation only in the last four years; however,

there has been modest development and no realization yet.

-- Drug-device combinations - Have achieved general acceptance over the

past six years, and as this trend toward convergence evolves, a second

wave of innovation suggests future realization activity.

-- Radiotherapy - A relatively mature innovation, radiotherapy has

experienced a recent burst of innovation over the past three years

resulting
'/>"/>

SOURCE Deloitte Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
2. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
5. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
7. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
8. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
9. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
10. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
11. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference